Read more: #FutureBiotechExpo #FBE26 #RedBiotechnology #BiotechInnovation #HealthcareInnovation #BiotechLeadership #ScientificBreakthroughs #LifeSciences #PharmaInnovation #HoustonEvents #DrugDiscovery #ClinicalResearch #Genomics #CellTherapy #GeneTherapy #MedTechAdvancement #BioTechConference #BioTechIndustry #HealthTech #BioPharma #NextGenBiotech #MedicalInnovation #BioRevolution To view or add a comment, sign in Accelerate your compound selection by understanding compound efficacy against fibrosis We have developed a high-throughput, high-sensitivity advanced in vitro FMT assay using human primary lung fibroblasts to study fibroblast activation and extracellular collagen I production following stimulation with the well-established fibrotic mediator TGF-1

Unlike current GLP-1 drugs that require weekly injections (like semaglutide or liraglutide), this oral formulation demonstrated: Significant weight loss over 72 weeks Improved blood sugar control in type 2 diabetes A safety profile consistent with known GLP-1 agents (mostly mild GI side effects) Why this matters: A pill is easier to use and store than injectables
When that same excess fat is driving sleep apnea, joint pain, prediabetes, or PCOS (now called PMOS), it becomes clinical obesity, a disease causing real harm
In the future, mutant strains with deletions of specific gene fragments, vaccines, or purified biomacromolecules could serve as essential alternatives in the prevention and treatment of invasive intestinal candidiasis